Companies · Other Health Care

Veran Medical Technologies, Inc.

ST. LOUIS · Other Health Care

Diligence memoA one-page analyst read on Veran Medical Technologies, Inc. — recommendation, valuation, rhythm, risks.
$130.9M
Total raised · real
13
Rounds
18.3×
Latest step-up
Top 4%
Sector rank · raised
Series C
Latest stage · inferred · Fri Sep 18 2015 00:00:00 GMT+0000 (Coordinated Universal Time)

Veran Medical Technologies, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.83× the median modeled value of Series C Other Health Care companies in 2013–2015 (33 peers) — value vs value, same stage and era.
  • Within the normal band (83% of peer median) for its niche.
Dormant
  • Last raise 10.8 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

Veran Medical Technologies, Inc. is one of 5376 Other Health Care companies tracked from ST. LOUIS. By capital raised it ranks among the largest (ahead of 97% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeed · 2009-08-11 Raised $1.4M (real) Modeled valuation $35M (est)Seed2009Seed · 2010-04-02 Raised $950K (real) Modeled valuation $24M (est)Seed2010Seed · 2010-09-28 Raised $484K (real) Modeled valuation $12M (est)Seed2010Series B · 2011-03-14 Raised $17M (real) Modeled valuation $374M (est)Series B2011Series A · 2011-03-14 Raised $9.9M (real) Modeled valuation $200M (est)Series A2011Series B · 2011-03-14 Raised $19M (real) Modeled valuation $423M (est)Series B2011Series B · 2011-03-14 Raised $19M (real) Modeled valuation $419M (est)Series B2011Series B · 2013-11-27 Raised $6.5M (real) Modeled valuation $144M (est)Series B2013Series B · 2013-11-27 Raised $4.8M (real) Modeled valuation $107M (est)Series B2013Series B · 2013-11-27 Raised $3.0M (real) Modeled valuation $65M (est)Series B2013Series B · 2013-11-27 Raised $5.0M (real) Modeled valuation $111M (est)Series B2013Series B · 2014-10-15 Raised $2.3M (real) Modeled valuation $51M (est)Series B2014Series C · 2015-09-18 Raised $42M (real) Modeled valuation $954M (est)Series C2015Cumulative $131M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.4M · 2009
Seed extension$950K · 2010
Seed extension$484K · 2010
Series B$16.9M · 2011no Series A on file
Bridge · Series B-stage$9.9M · 2011smaller follow-on
Series B extension$19.1M · 2011
Series B extension$18.9M · 2011
Series B extension$6.5M · 2013
Series B extension$4.8M · 2013
Series B extension$3.0M · 2013
Series B extension$5.0M · 2013
Series B extension$2.3M · 2014
Series C$41.7M · 2015

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 80%.

Modeled valuation trajectory
$953.8M
Base estimate est.
$151.6M
Conservative case
$2.5B
Upside case
$278.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Seed · modeled $34.7M · 2009-08-112009Seed · modeled $23.5M · 2010-04-02Seed · modeled $12.0M · 2010-09-28Series B · modeled $374.4M · 2011-03-14Series A · modeled $199.7M · 2011-03-14Series B · modeled $422.6M · 2011-03-14Series B · modeled $418.7M · 2011-03-14Series B · modeled $144.0M · 2013-11-27Series B · modeled $107.3M · 2013-11-27Series B · modeled $65.5M · 2013-11-27Series B · modeled $110.8M · 2013-11-27Series B · modeled $50.5M · 2014-10-15Series C · modeled $953.8M · 2015-09-182015
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
73%
Survival probability
55% low · 85% high
1.29×/yr
Annual markup
1.48×/yr upside case
6.0 yr
Elapsed time used
10.8 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
6 mo
Avg between rounds
$21.4M/yr
Capital velocity
16.9 yr
On record since
2009
First round
13
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 54× above median
This company$130.9M
Sector median$2.4M
Latest round — vs other Series C rounds in sector (real $, this stage) 0.9× of median
This company$41.7M
Sector median$45.9M
Modeled value — vs sector median (estimate, all stages) 43× above median
This company$953.8M
Sector median$22.1M

Raised more than 97% of sector peers (real $). Modeled value above 96% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #24 of 33.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)ACON IWP Holdings, L.L.C. · Series C Raised $91.8M · modeled $2.1B (est)Erc Group Holdings, Llc · Series C Raised $91.7M · modeled $2.1B (est)Cpf Senior Living Holdings, Llc · Series C Raised $158.4M · modeled $2.0B (est)Corvus Pharmaceuticals, Inc. · Series C Raised $87.7M · modeled $1.7B (est)TVG-SHC Holdings, LLC · Series C Raised $70.4M · modeled $1.6B (est)Wave Life Sciences Pte Ltd · Series C Raised $77.8M · modeled $1.5B (est)Sequel Youth & Family Services, LLC · Series C Raised $97.8M · modeled $1.5B (est)MedSynergies, Inc. · Series C Raised $118.0M · modeled $1.5B (est)HALT Medical, Inc · Series C Raised $177.7M · modeled $1.4B (est)Med Fusion, LLC · Series C Raised $92.9M · modeled $1.4B (est)Data Driven Delivery Systems, LLC · Series C Raised $67.0M · modeled $1.4B (est)Remedy Partners, Inc. · Series C Raised $110.0M · modeled $1.4B (est)Veran Medical Technologies, Inc. (this company) Raised $130.9M · modeled $953.8M (est)Veran Medical Technologies, Inc.
CompanyStageRaised · realValue · estvs peer med.
ACON IWP Holdings, L.L.C.Series C$91.8M$2.1B1.84×
Erc Group Holdings, LlcSeries C$91.7M$2.1B1.83×
Cpf Senior Living Holdings, LlcSeries C$158.4M$2.0B1.72×
Corvus Pharmaceuticals, Inc.Series C$87.7M$1.7B1.50×
TVG-SHC Holdings, LLCSeries C$70.4M$1.6B1.41×
Wave Life Sciences Pte LtdSeries C$77.8M$1.5B1.32×
Sequel Youth & Family Services, LLCSeries C$97.8M$1.5B1.32×
MedSynergies, Inc.Series C$118.0M$1.5B1.30×
HALT Medical, IncSeries C$177.7M$1.4B1.27×
Med Fusion, LLCSeries C$92.9M$1.4B1.22×
Data Driven Delivery Systems, LLCSeries C$67.0M$1.4B1.22×
Remedy Partners, Inc.Series C$110.0M$1.4B1.20×
Veran Medical Technologies, Inc. this companySeries C$130.9M$953.8M0.83×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.4M2009-08-11$7.0M$34.7M90%
Seed$950K2010-04-02$4.8M$23.5M90%
Seed$484K2010-09-28$2.4M$12.0M90%
Series B$16.9M2011-03-14$93.9M$374.4M90%
Series A$9.9M2011-03-14$45.0M$199.7M90%
Series B$19.1M2011-03-14$106.0M$422.6M90%
Series B$18.9M2011-03-14$105.0M$418.7M90%
Series B$6.5M2013-11-27$36.1M$144.0M90%
Series B$4.8M2013-11-27$26.9M$107.3M90%
Series B$3.0M2013-11-27$16.4M$65.5M90%
Series B$5.0M2013-11-27$27.8M$110.8M90%
Series B$2.3M2014-10-15$12.7M$50.5M90%
Series C$41.7M2015-09-18$278.1M$953.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.4M2009-08-11
    • First recorded raise — entered as Seed.
  2. Seed$950K2010-04-02
    • Came back fast: 8 mo vs the ~14 mo sector norm.
    • Round 1.5× smaller than the prior — bridge or down round.
  3. Seed$484K2010-09-28
    • Came back fast: 6 mo vs the ~14 mo sector norm.
    • Round 2.0× smaller than the prior — bridge or down round.
  4. Series B$16.9M2011-03-14
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round 34.9× larger than the prior — scaling up.
  5. Series A$9.9M2011-03-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.7× smaller than the prior — bridge or down round.
  6. Series B$19.1M2011-03-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.9× larger than the prior — scaling up.
  7. Series B$18.9M2011-03-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
  8. Series B$6.5M2013-11-27
    • Raised again after 32 mo — slower than the ~14 mo sector norm.
    • Round 2.9× smaller than the prior — bridge or down round.
  9. Series B$4.8M2013-11-27
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.3× smaller than the prior — bridge or down round.
  10. Series B$3.0M2013-11-27
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.6× smaller than the prior — bridge or down round.
  11. Series B$5.0M2013-11-27
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.7× larger than the prior — scaling up.
  12. Series B$2.3M2014-10-15
    • Raised 11 mo later, in step with the ~14 mo sector norm.
    • Round 2.2× smaller than the prior — bridge or down round.
  13. Series C$41.7M2015-09-18
    • Raised 11 mo later, in step with the ~14 mo sector norm.
    • Round 18.3× larger than the prior — scaling up.
Intelligence
2016 ~Q1
Modeled next raise · ~6mo cadence
$125.2M
Modeled next size est.range $81.4M$200.3M
18.3×
Last step-up
$21.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Greg Johnson8 other2015-09
David Adair6 other2013-11
Ajit Shah2 other2013-11
Frank Bonsal2 other2009-08
Jeremy R. Degenhart2 other2010-04
Robert Paulson1 other2009-08
Ajit W Shah2011-03
Curt Hartman2013-11
David W. Adair2011-03
Frank R Bonsal2010-04
Greg Johnon, Ph.D.2009-08
Gregory L. Johnson2013-11
Greg R Johnson, Ph.D2010-04
Jason Pesterfield2013-11
Jeremy Degenhart2009-08
Jerome R Edwards2009-08
Mark Hunter2015-09
Mark W Hunter2009-08
Maureen L. Oehler2013-11
Maureen Oehler2015-09
Richard Davis, MD2009-08
Richard R. Davis, MD2010-04
Robert L. Powers2013-11
Robert R Paulson2010-04
Registry & provenance

Veran Medical Technologies, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1312458
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
BioDerm Holdings, LPOther Health CareSeries C$130.9M$1.0Bsame sector · same stage
Alphatec Holdings, Inc.Other Health CareSeries C$133.7M$608.3Msame sector · same stage
Navvis & Company, LLCOther Health CareSeries C$133.9M$1.3Bsame sector · same stage
Vertiflex, Inc.Other Health CareSeries C$134.1M$1.0Bsame sector · same stage
Rapid Micro Biosystems, Inc.Other Health CareSeries C$134.6M$1.4Bsame sector · same stage
SpyGlassPharma, Inc.Other Health CareSeries C$134.8M$484.8Msame sector · same stage
Hello Heart Inc.Other Health CareSeries C$127.0M$1.0Bsame sector · same stage
Autonomic Technologies IncOther Health CareSeries C$125.6M$1.1Bsame sector · same stage
Frequently asked
How much funding has Veran Medical Technologies, Inc. raised?
Veran Medical Technologies, Inc. has raised approximately $130.9M in disclosed capital across 13 recorded financing rounds, aggregated from public filings.
What is Veran Medical Technologies, Inc.'s estimated valuation?
Provath's modeled valuation for Veran Medical Technologies, Inc. is approximately $953.8M (modeled range $151.6M–$2.5B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Veran Medical Technologies, Inc. at?
Veran Medical Technologies, Inc.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Fri Sep 18.
What does Veran Medical Technologies, Inc. do and where is it based?
Veran Medical Technologies, Inc. operates in the Other Health Care sector, based in ST. LOUIS.
Explore related

See where Veran Medical Technologies, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Veran Medical Technologies, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.